BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rier HN, Kharagjitsing H, van Rosmalen J, van Vugt J, Westerweel PE, de Jongh E, Kock M, Levin MD. Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2020;61:1618-26. [PMID: 32167390 DOI: 10.1080/10428194.2020.1737686] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Iltar U, Sözel H, Sözel YK, Ataş Ü, Yücel OK, Salim O, Aydin F, Undar L. Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy. Leukemia & Lymphoma 2021;62:1098-106. [DOI: 10.1080/10428194.2020.1856833] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lucijanic M, Huzjan Korunic R, Sedinic M, Kovacevic S, Atic A, Pejsa V, Kusec R. Baseline and progressive adipopenia in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features are associated with worse clinical outcomes. Leuk Lymphoma 2022;:1-10. [PMID: 35105266 DOI: 10.1080/10428194.2022.2034160] [Reference Citation Analysis]
3 Huang LW, Sun D, Link TM, Lang T, Ai W, Kaplan LD, Steinman MA, Andreadis C. High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas. Support Care Cancer 2021;29:5399-408. [PMID: 33694088 DOI: 10.1007/s00520-021-06120-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yoshida S, Sakurai G, Yahata T. Prevalence of low skeletal muscle quantity and quality and their associated factors in patients before allogeneic hematopoietic stem cell transplantation. Intern Emerg Med 2021. [PMID: 34387840 DOI: 10.1007/s11739-021-02828-3] [Reference Citation Analysis]
5 Albano D, Dondi F, Ravanelli M, Tucci A, Farina D, Giubbini R, Treglia G, Bertagna F. Prognostic Role of "Radiological" Sarcopenia in Lymphoma: A Systematic Review. Clin Lymphoma Myeloma Leuk 2022;22:e340-9. [PMID: 34893457 DOI: 10.1016/j.clml.2021.11.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lucijanic M, Huzjan Korunic R, Sedinic M, Kusec R, Pejsa V. More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features. Ther Clin Risk Manag 2021;17:1037-44. [PMID: 34594106 DOI: 10.2147/TCRM.S323749] [Reference Citation Analysis]
7 Lucijanić M, Korunić RH, Sedinić M, Kušec R, Pejša V. Prognostic impact of psoas muscle index in patients with diffuse large B-cell lymphoma might be dependent on the immunochemotherapy type. Leuk Lymphoma 2021;:1-4. [PMID: 33908324 DOI: 10.1080/10428194.2021.1919667] [Reference Citation Analysis]
8 Xu X, He D, Tian M, Wu H, Jin X. Prognostic Value of Sarcopenia in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A Systematic Review and Meta-Analysis. Front Nutr 2022;9:816883. [DOI: 10.3389/fnut.2022.816883] [Reference Citation Analysis]